ROCHESTER, Minn. — A recent study by Mayo Clinic published in the New England Journal of Medicine has revealed promising results for treating extramedullary multiple myeloma using a dual-antibody therapy.

"We are seeing powerful responses in a disease that historically has resisted every therapy," Shaji Kumar, M.D., a hematologist at Mayo Clinic, said.

The therapy employs talquetamab and teclistamab to engage T cells and attack myeloma cells through two immune pathways. The study says in a trial with 90 patients, 79% responded to the treatment, and 54% showed no detectable disease.

Nearly two-thirds maintained disease control for a year, offering hope for a subtype with typically poor prognosis. Serious side effects, including infection, highlight the need for comprehensive care dur

See Full Page